Excitement about the sales potential of GLP-1 agonists for the treatment of obesity is so strong that Novo Nordisk A/S is boasting about the performance of its top-seller in the class, Wegovy (semaglutide), nearly three weeks ahead of its first quarter earnings report scheduled for 4 May. The Danish big pharma announced on 13 April that its total product sales increased 25% in Q1 versus the same period in 2022, largely due to increased US demand for Wegovy, and it now is projecting 24%-30% companywide sales growth for the year, up from prior guidance of 13%-19%.
Novo also said operating profit growth was 28% in the first quarter and the company now expects operating profit growth...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
